Stocks Health care CNMD
NYSE · Health careCONMED Corp (CNMD)
CONMED Corp reported revenue of $1.4B in fiscal 2025, up 5.2% from a year earlier. Net income was $47.1M, a net margin of 3.4%. Operating cash flow minus capital spending left $150.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $48M in cash against $815.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 28, 2026.
Key facts about CONMED Corp
- Net worth
- CONMED Corp has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.4B (+5.2% year on year), with net income of $47.1M.
- Cash flow
- In fiscal 2025 operations brought in $170.7M of cash; after $19.8M of capital spending, free cash flow was $150.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 28, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- CONMED Corp's next report is expected around January 27, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- CONMED Corp declared dividends of $0.60 per share in fiscal 2025, a yield of 1.18% at the current price.
What CONMED Corp does
CONMED Corp is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on NYSE under the ticker CNMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.4B | $47.1M | $1.51 | $150.9M |
| 2024 | $1.3B | $132.4M | $4.25 | $153.9M |
| 2023 | $1.2B | $64.5M | $2.04 | $106.3M |
| 2022 | $1B | -$80.6M | -$2.68 | $11.6M |
| 2021 | $1B | $62.5M | $1.94 | $96.9M |
| 2020 | $862.5M | $9.5M | $0.32 | $51.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CNMD ranks in Health care
Dividends
CONMED Corp declared $0.60 per share in fiscal 2025. At the current price that is a yield of 1.18%. It paid out $24.7M in cash dividends, 53% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $0.60 | $24.7M | 53% |
| 2024 | $0.80 | $24.7M | 19% |
| 2023 | $0.80 | $24.5M | 38% |
| 2022 | $0.80 | $24M | n/a |
| 2021 | $0.80 | $23.3M | 37% |
| 2020 | $0.80 | $22.8M | 240% |
Latest SEC filings
What CONMED Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 28, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 0.7% to $335.6M versus the same quarter last year; diluted EPS $0.66 versus $0.09.
- October 28, 2026
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was flat at $343.5M versus the same quarter last year; diluted EPS $0.77 versus $0.69.
- July 29, 2026
- June 17, 2026
- June 16, 2026
- June 4, 2026
- June 1, 2026
- May 28, 2026
- May 20, 2026
What is CNMD worth? A DCF from its reported cash flow
Insider trades
What the people running CONMED Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Foust Hollie KGeneral Counsel & Corp Sec | Exercised options | 4,000 | - |
| November 4, 2026 | Foust Hollie KGeneral Counsel & Corp Sec | Shares withheld for tax | 1,124 | $60.3K |
| September 8, 2026 | Kelderman KimDirector | Exercised options | 500 | - |
| June 2, 2026 | Schwarzentraub Barbara JDirector | Exercised options | 668 | - |
| June 2, 2026 | Kaye MarkDirector | Exercised options | 668 | - |
| June 2, 2026 | Farkas CharlesDirector | Exercised options | 668 | - |
| June 2, 2026 | Council LaVerne HDirector | Exercised options | 668 | - |
| June 2, 2026 | Bronson David M.Director | Exercised options | 668 | - |
Who owns CNMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| EARNEST Partners, LLC -------------------------------------------------------------------------------13G, passive | 9% | November 13, 2024 |
| Vanguard Portfolio Management13G, passive | 6.87% | April 29, 2026 |
| Fuller & Thaler Asset Management, Inc.13G, passive | 5.63% | August 14, 2025 |
| Vanguard Capital Management13G, passive | 5.25% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 246 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 4,820,739 | -4,434 |
| Earnest Partners LLC | 2,505,295 | -64,358 |
| Vanguard Portfolio Management LLC | 2,188,761 | +112,344 |
| Fuller & Thaler Asset Management, Inc. | 1,579,917 | -61,849 |
| State Street Corp | 1,417,468 | +33,450 |
| Vanguard Capital Management LLC | 1,355,728 | -28,314 |
| Bank of America Corp | 1,341,409 | -61,211 |
| Dimensional Fund Advisors LP | 1,317,370 | -75,550 |
| Sei Investments Co | 988,151 | -16,564 |
| Invenomic Capital Management LP | 842,162 | -92,439 |
| Capital Research Global Investors | 823,636 | -101,812 |
| Geode Capital Management, LLC | 790,138 | +47,531 |
| Two Sigma Investments, LP | 728,976 | -53,564 |
| Allspring Global Investments Holdings, LLC | 618,447 | +35,714 |
| Cooke & Bieler LP | 573,498 | -414,285 |
| Paradigm Capital Management Inc | 538,245 | new |
| Arrowstreet Capital, Limited Partnership | 476,885 | +57,793 |
| Charles Schwab Investment Management Inc | 471,022 | -7,581 |
| Silvercrest Asset Management Group LLC | 441,361 | -207,216 |
| Goldman Sachs Group Inc | 436,830 | -39,818 |
Insiders
8 insiders reported holding 51,161 shares in total, about $2.6M at the last price.
| Holder | Shares |
|---|---|
| Bronson David M.Director | 17,909 |
| Farkas CharlesDirector | 15,527 |
| Foust Hollie KGeneral Counsel & Corp Sec | 5,762 |
| Schwarzentraub Barbara JDirector | 5,012 |
| Council LaVerne HDirector | 4,716 |
| Lalomia BrentExecutive VP RA, QA | 915 |
| Kaye MarkDirector | 820 |
| Kelderman KimDirector | 500 |
Questions about CNMD
What does CONMED Corp do?
CONMED Corp is a company in the Health care sector, listed on NYSE as CNMD. Its shares trade on NYSE under the ticker CNMD.
What is CONMED Corp's net worth?
CONMED Corp has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is CONMED Corp profitable?
Yes. In fiscal 2025 it reported net income of $47.1M on revenue of $1.4B, a net margin of 3.4%.
How much revenue does CONMED Corp make?
In fiscal 2025 CONMED Corp reported revenue of $1.4B. That is 5.2% more than a year earlier.
When did CONMED Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 28, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is CONMED Corp's next earnings report?
CONMED Corp's next report is expected around January 27, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Does CONMED Corp pay a dividend?
Yes. CONMED Corp declared dividends of $0.60 per share in fiscal 2025, a yield of 1.18% at the current price.
Similar companies
Compare CNMD with
Follow CNMD
Get an email when CONMED Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values CONMED Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.